ENLItN

  • Research type

    Research Study

  • Full title

    Eastern and North Western Lung Cancer In Never-Smokers Cohort

  • IRAS ID

    335582

  • Contact name

    Frank McCaughan

  • Contact email

    fm319@cam.ac.uk

  • Sponsor organisation

    Cambridge University Hospitals NHS Foundation Trust and University of Cambridge

  • Duration of Study in the UK

    8 years, 0 months, 0 days

  • Research summary

    The purpose of this study is to first establish a cohort of patients with never-smoking lung cancer or with lung cancer that has one of the gene alterations commonly seen in never-smoking lung cancer; and then to try to understand what the links are between the disease and inherited or acquired/environmental risk.

    Lung Cancer in Never-Smokers (LCINS) is responsible for approximately 1/6th of all lung cancers. The cause is poorly understood and there is little detailed information available in the UK about patients who have been affected.

    Key Question
    The majority of patients with lung cancer have a history of smoking. When someone is diagnosed with lung cancer having not smoked cigarettes a recurrent question is “Why me?”. This proposal is designed to address that question.

    The approach?
    We aim to use a combination of genetic and environmental profiling in patients with lung cancer to build an understanding of why an individual may have developed the disease. We will then assess whether signatures of the disease can be picked up in a blood test.

    For this we need to perform genetic tests on patient tissue and blood and ask questions about previous environmental exposure. We will ask participants to complete a detailed questionnaire about their lifetime environmental exposure and agree to a blood sample.

    We will also ask for access to archived tumour tissue, or DNA derived from tissue, that is no longer relevant to clinical decision-making.

    The questionnaire will be used to estimate, measure and understand environmental exposures that an individual may have experienced. Genetic sequencing will be performed on the tissue and blood specimens. This will create a dataset of signatures which we can then use to assess correlation between an individual’s genetic signature and their specific environmental exposures. From this we can try to define a UK risk profile for LCINS.

  • REC name

    London - West London & GTAC Research Ethics Committee

  • REC reference

    24/PR/1513

  • Date of REC Opinion

    17 Jan 2025

  • REC opinion

    Further Information Favourable Opinion